March 23, 2015
TB Alliance Announces Partnership with U.S. Fund for UNICEF to Increase Access to Impending New Child-Friendly TB Treatments
Collaboration seeks to pull more sick children out of the shadows and into treatment for tuberculosis March 17, 2015
Global Phase 3 “STAND” Trial Launched to Test New Tuberculosis Drug Regimen PaMZ to Shorten, Improve Treatment
March 17, 2015
The Lancet: Results of Phase 2b Trial of Novel TB Regimen PaMZ Show Potential to Shorten, Improve TB Treatment
Phase 3 STAND Trial Launches to Advance PaMZ through Final Stage of Testing February 17, 2015
TB Alliance Advances Next-generation TB Drug Candidate into Clinical Testing
TBA-354 is the first potential tuberculosis drug to advance to Phase 1 trial in six years January 28, 2015
Phase 2a Published Results Show the Potential of a New TB Regimen with Novel Drugs Bedaquiline and Pretomanid (PA-824)
Results of study testing BPaZ published in American Journal of Respiratory and Critical Care Medicine; Regimen now being tested in Phase 2b clinical trial January 7, 2015
TB Alliance Announces Two New Members to Its Board of Directors: Dr. Mario Raviglione of WHO and Shalini Sharp of Ultragenyx
December 18, 2014
Developing New Tuberculosis Drugs from Marine Natural Products: Joint research program between OPBIO and TB Alliance announced
November 9, 2014
Summary of TB Alliance & UNITAID symposium on the Pediatric TB Drug Market (full presentations available)
October 21, 2014
TB Alliance Launches Phase 2B Clinical Trial of a Novel TB Drug Regimen that Could Cut Treatment Time by Half or More for a Majority of TB Patients
NC-005 trial tests a novel regimen of bedaquiline (Sirturo), pretomanid (formerly known as PA-824), and pyrazinamide; results could pave the way for a three-month TB treatment October 20, 2014